Welcome to our dedicated page for Psyence Biomedical Ltd. news (Ticker: PBM), a resource for investors and traders seeking the latest updates and insights on Psyence Biomedical Ltd. stock.
Psyence Biomedical Ltd. (Nasdaq: PBM), also known as Psyence BioMed, is a biopharmaceutical and life sciences biotechnology company focused on nature-derived psilocybin and ibogaine-based psychedelic medicine. Its news flow reflects activity across clinical development, manufacturing, capital markets, and strategic partnerships.
Readers of the PBM news page can expect updates on the company’s Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for Adjustment Disorder in palliative care or in patients with cancer. News releases describe milestones such as patient dosing, expansion of clinical sites in Australia, and ethics approvals for the use of PsyLabs’ psilocybin product in the trial.
The company also issues announcements on its ibogaine operations and supply chain, including the establishment of sustainable iboga bark sourcing in Africa and the production of GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) and Total Alkaloid Extracts through its partner PsyLabs. These updates highlight progress in securing psychedelic active pharmaceutical ingredients for clinical and therapeutic markets.
Other PBM news items cover strategic investments and financial decisions, such as follow-on investments in PsyLabs, share consolidation (reverse stock split) actions, and capital management frameworks that include potential share repurchase programs, as described by the company. Communications may also address leadership changes, board appointments, and corporate governance developments disclosed in conjunction with SEC filings.
In addition, Psyence BioMed publishes news on its psilocybin longevity research initiative, which examines biological markers associated with aging, and on its broader positioning in the emerging psychedelics and longevity sectors. Investors and observers who follow PBM news can use this page to track the company’s clinical progress, manufacturing capabilities, and regulatory and capital markets updates over time.
Psyence BioMed (NASDAQ: PBM) says it has built a GMP-compliant, vertically integrated ibogaine supply chain via investment and collaboration with PsyLabs, operating at the natural source in Africa. The company holds standardized, stabilized GMP ibogaine doses in inventory to support clinical research and potential commercialization.
Platform covers sourcing, extraction, purification, pharmaceutical manufacturing, traceability, and ethical in-region processing.
Psyence BioMed (Nasdaq: PBM) on April 17, 2026 acknowledged U.S. executive action preparations to evaluate ibogaine’s safety and therapeutic potential, while emphasizing its global leadership in GMP ibogaine manufacturing and an ethically sourced supply chain via PsyLabs.
Ibogaine remains a Schedule I substance in the U.S.; the company says controlled clinical research and standardized supply are essential to improve patient safety and enable regulated development.
Psyence BioMed (Nasdaq: PBM) expanded its Australian clinical site network from three to five sites on April 8, 2026, adding Ramsay Health Care and NeuroCentrix.
The move supports the ongoing multi-site Phase IIb trial of pharmaceutical-grade psilocybin NPX-5 for Adjustment Disorder in palliative oncology, aims to accelerate enrollment, and broadens geographic reach.
Psyence BioMed (NASDAQ: PBM) announced that its strategic investment in PsyLabs builds a vertically integrated, GMP-compliant pharmaceutical platform supporting psilocybin and ibogaine development.
PsyLabs is licensed, debt-free, and exported its first clinical-trial product to Australia, while the company reports no corporate debt and a focus on disciplined capital allocation.
Psyence BioMed (Nasdaq: PBM) exported GMP-manufactured natural psilocybin NPX-5 (1 mg and 5 mg capsules) to Australia to supply its ongoing Phase IIb trial for Adjustment Disorder in palliative oncology.
The multi-center, double-blind trial is enrolling 87 participants across Australian sites including Melbourne and Perth; patient dosing began in late 2025 and newly enrolled patients will receive NPX-5. PsyLabs manufactured the product and holds a 49.98% equity stake in Psyence BioMed.
Psyence BioMed (Nasdaq: PBM) announced that Psyence Labs exercised a previously disclosed put option, triggering a share-for-share equity investment in PsyLabs valued at US$5,000,000.
The Company will receive 2,900 PsyLabs shares and issue 1,146,159 PBM shares; closing is expected on or about February 25, 2026. No cash will change hands and the transaction would leave PsyLabs with ~49.98% of PBM outstanding shares.
Psyence BioMed (Nasdaq: PBM) reported results from its Annual and Special Meeting held Feb 12, 2026. Shareholders approved all matters, including election of directors, appointment of MNP LLP as auditors, and a special resolution authorizing the Board to implement one or more share consolidations up to 250:1.
All director nominees listed in the company's management information circular dated Jan 2, 2026 were elected to hold office until the next annual meeting. The Board will disclose final consolidation ratio and effective date if it decides to proceed, subject to regulatory and exchange approvals.
Psyence BioMed (Nasdaq: PBM) approved a Put Option Agreement with PsyLabs on Feb 13, 2026 to secure long-term access to GMP pharmaceutical-grade psilocybin and ibogaine supply while preserving near-term cash. The option allows PsyLabs to require a future share-for-share equity investment at fair market value, and the Board formed a Special Committee and relied on an independent valuation.
Psyence BioMed (Nasdaq: PBM) announced a settlement resolving a direct shareholder claim by KAOS Capital dated Jan 14 and Jan 26, 2026. The Ontario Superior Court dismissed KAOS's application and awarded costs of CDN $75,000. Under the settlement the company will pay US $1,500,000 and KAOS will sell all its shares at US $5 per share, include a full retraction and mutual release, and KAOS is released from the Costs Award. The company expects to fund the payment from cash on hand and record it under applicable accounting standards.
Psyence BioMed (Nasdaq: PBM) announced its 1-for-6.25 reverse stock split will become effective at market open on February 2, 2026. The consolidation changes issued and outstanding common shares from 6,388,604 to 1,022,177 and keeps the ticker PBM.
Outstanding warrants and equity instruments will be adjusted proportionately; new CUSIP is 74449F407. No fractional shares will be issued; fractions are rounded per disclosed rules. Book-entry holders need take no action; beneficial holders should consult brokers.